Antibody-Drug Conjugate (ADC) CDMO Market
完整報告名稱與涵蓋範圍
Antibody-Drug Conjugate (ADC) CDMO Market Size, Share & Trends Analysis Report, By Service Type (Antibody Manufacturing, Payload and Linker Synthesis, Bioconjugation, Fill-Finish and Drug Product Manufacturing, Analytical and Development Services), By Conjugation Technology (Lysine-Based Conjugation, Cysteine-Based Conjugation, Site-Specific and Enzymatic Conjugation), By Development Stage (Preclinical and Clinical, Commercial), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
The antibody-drug conjugate CDMO market covers outsourced development and manufacturing across the ADC value chain, including antibody production, cytotoxic payload and linker synthesis, bioconjugation, sterile fill-finish and the analytical services that tie these steps together. Captive manufacturing by ADC originators and the therapeutic product market are excluded from revenue but analysed as demand drivers.
Outsourcing intensity in ADCs is among the highest of any modality because few sponsors possess high-potency containment, conjugation chemistry and biologics capabilities under one roof. A pipeline of several hundred candidates, a series of blockbuster approvals and large licensing deals for China-originated ADCs have translated into sustained demand for conjugation slots, payload-linker capacity and specialised fill-finish. Providers are integrating end-to-end offerings, adding site-specific and enzymatic conjugation platforms, expanding high-potency suites and building dedicated ADC campuses, while sponsors seek supply security through multi-site and dual-sourcing arrangements.
Europe, the United States, South Korea and China host the principal capacity, with Chinese and Korean providers growing fastest on the strength of domestic pipelines and cost-competitive offerings. Competition involves integrated global CDMOs, conjugation specialists and payload-focused chemistry manufacturers.
The InsightAce study includes revenue forecasts in US$ for all service type, conjugation technology, development stage and end user and regional segments across 2026-2035, segment-level trend analysis, competitive positioning assessment and company profiles.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Antibody-Drug Conjugate (ADC) CDMO Market Snapshot
Chapter 4. Global Antibody-Drug Conjugate (ADC) CDMO Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Service Type Estimates & Trend Analysis
5.1. Service Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Service Type:
5.2.1. Antibody Manufacturing
5.2.2. Payload and Linker Synthesis
5.2.3. Bioconjugation
5.2.4. Fill-Finish and Drug Product Manufacturing
5.2.5. Analytical and Development Services
Chapter 6. Market Segmentation 2: By Conjugation Technology Estimates & Trend Analysis
6.1. Conjugation Technology & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Conjugation Technology:
6.2.1. Lysine-Based Conjugation
6.2.2. Cysteine-Based Conjugation
6.2.3. Site-Specific and Enzymatic Conjugation
Chapter 7. Market Segmentation 3: By Development Stage Estimates & Trend Analysis
7.1. Development Stage & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Development Stage:
7.2.1. Preclinical and Clinical
7.2.2. Commercial
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. End User & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
8.2.1. Large Pharmaceutical Companies
8.2.2. Biotechnology Companies
Chapter 9. Antibody-Drug Conjugate (ADC) CDMO Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Lonza Group AG
11.2. WuXi XDC Cayman Inc.
11.3. Samsung Biologics Co., Ltd.
11.4. Merck KGaA
11.5. AGC Biologics
11.6. Piramal Pharma Solutions
11.7. Sterling Pharma Solutions
11.8. Abzena Ltd.
11.9. Novo Nordisk A/S (Catalent)
11.10. Fujifilm Diosynth Biotechnologies
11.11. MilliporeSigma (BioReliance)
11.12. Bachem Holding AG
11.13. Boehringer Ingelheim International GmbH
11.14. Iksuda Therapeutics (Synaffix Technology Users)
11.15. Cerbios-Pharma SA
圖表清單 List of Tables & Figures
Table 1. Global Antibody-Drug Conjugate (ADC) CDMO Market Revenue Forecast by Service Type, 2026-2035 (US$ Mn)
Figure 1. Global Antibody-Drug Conjugate (ADC) CDMO Market Segmentation and Scope Overview
Table 2. Global Antibody-Drug Conjugate (ADC) CDMO Market Revenue Forecast by Conjugation Technology, 2026-2035 (US$ Mn)
Figure 2. Global Antibody-Drug Conjugate (ADC) CDMO Market Share by Service Type, 2026 & 2035
Table 3. Global Antibody-Drug Conjugate (ADC) CDMO Market Revenue Forecast by Development Stage, 2026-2035 (US$ Mn)
Figure 3. ADC Manufacturing Value Chain and Outsourcing Points from Antibody to Fill-Finish
Table 4. Global Antibody-Drug Conjugate (ADC) CDMO Market Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 4. ADC Clinical Pipeline Growth and Conjugation Capacity Demand, 2026-2035
Table 5. Global Antibody-Drug Conjugate (ADC) CDMO Market Revenue Forecast by Region, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Antibody-Drug Conjugate (ADC) CDMO Growth Opportunity Analysis
Table 6. North America Antibody-Drug Conjugate (ADC) CDMO Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Competitive Positioning of Key Antibody-Drug Conjugate (ADC) CDMO Market Participants
Table 7. Europe Antibody-Drug Conjugate (ADC) CDMO Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Porter's Five Forces Analysis of the Global Antibody-Drug Conjugate (ADC) CDMO Market
Table 8. Asia Pacific Antibody-Drug Conjugate (ADC) CDMO Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Integrated Versus Specialist ADC CDMO Positioning by Capability
Table 9. Strategic Developments of Leading Antibody-Drug Conjugate (ADC) CDMO Market Participants, 2023-2026
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們